Regencell Bioscience (NASDAQ:RGC) Trading Down 3.9% – Should You Sell?

Regencell Bioscience Holdings Limited (NASDAQ:RGC)’s stock price traded down 3.9% on Friday . The stock traded as low as $5.22 and last traded at $5.23. 93,399 shares changed hands during trading, a decline of 70% from the average session volume of 307,115 shares. The stock had previously closed at $5.44.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Wall Street Zen lowered shares of Regencell Bioscience from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Wednesday, June 24th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Sell”.

Regencell Bioscience Trading Down 3.5%

The firm’s fifty day moving average price is $7.19 and its two-hundred day moving average price is $19.89.

Hedge Funds Weigh In On Regencell Bioscience

A number of hedge funds have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC bought a new stake in shares of Regencell Bioscience in the 2nd quarter worth $1,701,000. BNP Paribas Financial Markets bought a new stake in shares of Regencell Bioscience during the 2nd quarter worth $768,000. XTX Topco Ltd bought a new stake in shares of Regencell Bioscience during the 3rd quarter worth $598,000. Vident Advisory LLC boosted its holdings in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Regencell Bioscience by 59,113.8% during the first quarter. Bank of America Corp DE now owns 17,172 shares of the company’s stock valued at $437,000 after buying an additional 17,143 shares during the period. Institutional investors and hedge funds own 0.13% of the company’s stock.

Regencell Bioscience Company Profile

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.